Eiger Bio to Participate in November 2020 Investor Conferences
Stifel Virtual Healthcare Conference. Eiger will present a corporate update on Wednesday, November 18, 2:00-2:30 PM ET. Jefferies Virtual London Healthcare Conference. Eiger will present a corporate update on Thursday, November 19, 6:10-6:40 PM GMT.
Eiger will host one-on-one meetings at both conferences. Live webcasts of the presentations will be available on the
Eiger is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs.
Eiger's lead clinical programs target Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis. Eiger is developing two complementary treatments for HDV. Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial. Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.
Eiger has filed an NDA and MAA for lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies. FDA PDUFA date is
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Investors and Media:
View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-bio-to-participate-in-november-2020-investor-conferences-301170676.html